MedTrace Logo

Circulating Tumor Cells (CTC) in Lung Cancer

NCT02630615 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2026-04-24

No results posted yet for this study

Summary

The primary objective of this study is to establish circulating tumor cell (CTC) derived xenografts and assess the activity of novel DNA repair inhibitors as a function of DNA repair mutations detected in CTC samples (personalize DNA repair therapy).

Conditions

  • Lung Neoplasms

Interventions

OTHER

Blood draw

Whole blood will be collected using standard phlebotomy procedures

Sponsors & Collaborators

  • Shadia Jalal

    lead OTHER

Principal Investigators

  • Shadia Jalal, MBBS · Indiana University School of Medicine, Indiana University Simon Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-19
Primary Completion
2026-10-31
Completion
2026-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02630615 on ClinicalTrials.gov